Enliven Therapeutics
ELVN
62 hedge funds and large institutions have $541M invested in Enliven Therapeutics in 2023 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 23 increasing their positions, 13 reducing their positions, and 7 closing their positions.
77% more repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 13
14% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 7
2% more funds holding
Funds holding: 61 → 62 (+1)
1% more capital invested
Capital invested by funds: $534M → $541M (+$7.11M)
0.13% less ownership
Funds ownership: 94.96% → 94.83% (-0.13%)
20% less funds holding in top 10
Funds holding in top 10: 5 → 4 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$18.2M |
| 2 |
BlackRock
New York
|
+$3.45M |
| 3 |
Janus Henderson Group
London,
United Kingdom
|
+$1.62M |
| 4 |
Morgan Stanley
New York
|
+$1.53M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$967K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$16.6M |
| 2 |
FLSM
Frazier Life Sciences Management
Palo Alto,
California
|
-$14.3M |
| 3 |
JC
JBF Capital
Aspen,
Colorado
|
-$369K |
| 4 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$245K |
| 5 |
AQR Capital Management
Greenwich,
Connecticut
|
-$177K |
ELVN Hedge Fund Activity: Q4 2023 in Review
62 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Enliven Therapeutics (ELVN) for Q4 2023, worth a combined $541M — up 1.3% from $534M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new ELVN positions and 7 closed out — a net gain of 1 holder — while 23 added to existing stakes and 13 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $18.2M. The largest seller was Cormorant Asset Management, exiting entirely with an estimated $16.6M sold.
- 62 institutional investors held Enliven Therapeutics (ELVN) as of Q4 2023, up from 61 in Q3 2023.
- Funds reported $541M of Enliven Therapeutics stock for Q4 2023, up 1.3% quarter-over-quarter.
- 8 funds opened new Enliven Therapeutics positions in Q4 2023 and 7 closed out, a net change of +1 holder.
- The largest Enliven Therapeutics buyer in Q4 2023 was Fidelity Investments, an estimated $18.2M added.
- The largest Enliven Therapeutics seller in Q4 2023 was Cormorant Asset Management, an estimated $16.6M sold.
Based on aggregated 13F filings for Q4 2023.